Health stocks followed the broader market rollercoaster Friday -- a light news day for the sector despite the volatility.

The Nasdaq and Amex biotechnology indices ended down 3.2% and 3.56%, after rebounding from losses as great as 8% earlier in the day.

The Amex pharmaceutical index settled on a loss of 6.21, or 2.55%, at 237.48 by late afternoon -- every single component was in the red. Wyeth ( WYE) and Teva ( TEVA) led losses, giving up 6.5% and 4.21%, respectively.

One of the few components of the Amex biotech index in positive territory, Intermune ( ITMN) shares gained 72 cents, or 5.3%, to $14.33 in late afternoon. No news was released.

Meanwhile, Biogen Idec ( BIIB) said late Thursday that it is stopping development of baminercept in rheumatoid arthritis, after a failed midstage study. Shares were down $1.98, or 4.42%, at $42.78.

Medicis ( MRX) said the FDA approved new labeling about the long-term effectiveness of wrinkle-filling drug Restylane based on new data. Medicis shares added $1.32, or 12.45%, to $11.92.

Next week Genentech ( DNA) will kick off biotech earnings, followed by Gilead ( GILD) on Thursday. Genentech shares closed down $5.75, or 7.3%, to $73, and Gilead closed lost $2.57, or 6.4%, to $37.47.

If you liked this article you might like

The Most Beloved Brands in America

CEOs Focus on Growth in 2010

CEOs Focus on Growth in 2010

A Peek at Jim Cramer's Portfolio

Glaxo, Wyeth Cut Costs With Trial Software

Glaxo, Wyeth Cut Costs With Trial Software

Biotech Stock Mailbag: Oncothyreon

Biotech Stock Mailbag: Oncothyreon